Voyager Therapeutics Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million

Reuters03-10

Voyager <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million

Voyager reported Q4 collaboration revenue of USD 15.34 million, up 144%, driven mainly by higher revenue recognized under its Neurocrine agreement. Q4 net loss was USD 27.43 million, while R&D expenses were USD 35.95 million and G&A expenses were USD 9.32 million. For FY2025, collaboration revenue was USD 40.37 million, down 50% due mainly to higher collaboration revenue recognized in FY2024 tied to the Neurocrine and Novartis agreements, and net loss was USD 119.72 million. Voyager ended FY2025 with cash, cash equivalents and marketable securities of USD 201.69 million and said it expects its cash runway to extend into 2028. Management said 2026 priorities include first-in-human dosing of its tau-silencing gene therapy VY1706 in H2 2026 and tau PET imaging data from the VY7523 Alzheimer’s MAD trial in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9667607) on March 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618367108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618367108","market":"us","top_or_hot":-1,"title":"Voyager Therapeutics Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Voyager <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Voyager reported Q4 collaboration revenue of USD 15.34 million, up 144%, driven mainly by higher revenue recognized under its Neurocrine agreement. Q4 net loss was USD 27.43 million, while R&amp;D expenses were USD 35.95 million and G&amp;A expenses were USD 9.32 million. For FY2025, collaboration revenue was USD 40.37 million, down 50% due mainly to higher collaboration revenue recognized in FY2024 tied to the Neurocrine and Novartis agreements, and net loss was USD 119.72 million. Voyager ended FY2025 with cash, cash equivalents and marketable securities of USD 201.69 million and said it expects its cash runway to extend into 2028. Management said 2026 priorities include first-in-human dosing of its tau-silencing gene therapy VY1706 in H2 2026 and tau PET imaging data from the VY7523 Alzheimer’s MAD trial in H2 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VYGR\">Voyager Therapeutics Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9667607) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Voyager Therapeutics Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVoyager Therapeutics Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Voyager <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Voyager reported Q4 collaboration revenue of USD 15.34 million, up 144%, driven mainly by higher revenue recognized under its Neurocrine agreement. Q4 net loss was USD 27.43 million, while R&amp;D expenses were USD 35.95 million and G&amp;A expenses were USD 9.32 million. For FY2025, collaboration revenue was USD 40.37 million, down 50% due mainly to higher collaboration revenue recognized in FY2024 tied to the Neurocrine and Novartis agreements, and net loss was USD 119.72 million. Voyager ended FY2025 with cash, cash equivalents and marketable securities of USD 201.69 million and said it expects its cash runway to extend into 2028. Management said 2026 priorities include first-in-human dosing of its tau-silencing gene therapy VY1706 in H2 2026 and tau PET imaging data from the VY7523 Alzheimer’s MAD trial in H2 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VYGR\">Voyager Therapeutics Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9667607) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065171402.SGD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL9qYNDt:1","article_id":"2618367108","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618367108","pubTimestamp":1773086511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Voyager reported Q4 collaboration revenue of USD 15.34 million, up 144%, driven mainly by higher revenue recognized under its Neurocrine agreement. Q4 net loss was USD 27.43 million, while R&D expenses were USD 35.95 million and G&A expenses were USD 9.32 million. For FY2025, collaboration revenue was USD 40.37 million, down 50% due mainly to higher collaboration revenue recognized in FY2024 tied to the Neurocrine and Novartis agreements, and net loss was USD 119.72 million. Voyager ended FY2025 with cash, cash equivalents and marketable securities of USD 201.69 million and said it expects its cash runway to extend into 2028. Management said 2026 priorities include first-in-human dosing of its tau-silencing gene therapy VY1706 in H2 2026 and tau PET imaging data from the VY7523 Alzheimer’s MAD trial in H2 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","NBIX":"神经分泌生物科学","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","VYGR":"Voyager Therapeutics Inc","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Voyager Therapeutics第四季度净亏损收窄至2743万美元，合作收入增长144%至1534万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":0.9,"NDAQ":0.9,"VYGR":0.9},"content_text":"Voyager Therapeutics Q4 net loss narrows to USD 27.43 million as collaboration revenue rises 144% to USD 15.34 million\n    \n\n        Voyager reported Q4 collaboration revenue of USD 15.34 million, up 144%, driven mainly by higher revenue recognized under its Neurocrine agreement. Q4 net loss was USD 27.43 million, while R&D expenses were USD 35.95 million and G&A expenses were USD 9.32 million. For FY2025, collaboration revenue was USD 40.37 million, down 50% due mainly to higher collaboration revenue recognized in FY2024 tied to the Neurocrine and Novartis agreements, and net loss was USD 119.72 million. Voyager ended FY2025 with cash, cash equivalents and marketable securities of USD 201.69 million and said it expects its cash runway to extend into 2028. Management said 2026 priorities include first-in-human dosing of its tau-silencing gene therapy VY1706 in H2 2026 and tau PET imaging data from the VY7523 Alzheimer’s MAD trial in H2 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603091601PRIMZONEFULLFEED9667607) on March 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618367108","isCrawlerRequest":true}